Aktuelle Ringversuche

Getestete Parameter:

Molekulargenetik - HLA-DQ:

HLA DQA1*05, HLA DQB1*02, HLA DQB1*03:02

Getestete Parameter:

Ringversuch zur Fäzes-Diagnostik

Calprotectin, Pankreat. Elastase, Calprotectin qualitativ, Pankreat. Elastase qual.

Getestete Parameter:

Wirkstoff- und Abstinenzkontrolle im Urin

Getestete Parameter:

Tuberkulosediagnostik:

Anzüchtung von Mykobakterien; Differenezierung von Tuberkulosebakterien

Getestete Parameter:

Qualitative Suchanalyse

Getestete Parameter:

Tuberkulosediagnostik 05:

Empfindlichkeitsprüfung von Tuberkulosebakterien

Getestete Parameter:

Web-basierter Ringversuch für Zytospinpräparate (Liquor):

Morphologie und Diagnose

Getestete Parameter:

Ringversuch zur quantitativen Bestimmung von GHB in Serum und Urin

Getestete Parameter:

Ringversuch zur quantitativen Bestimmung von GHB in Serum und Urin

Getestete Parameter:

Ringversuch zur quantitativen Bestimmung von Antiepileptika in Serum:

Carbamazepin,10-OH-Carbazepin, Oxcarbazepin,Felbamat, Pregabalin, Gabapentin, Levetiracetam, Topiramat, Vigabatrin, Lamotrigin, Lacosamid, Rufinamid, Zonisamid

Getestete Parameter:

Ringversuch zur quantitativen Bestimmung von Metanephrin und Metabolite in Plasma:

Metanephrin, 3-Methoxytyramin, Normetanephrin

Getestete Parameter:

Anti-Schistosoma IgG

Getestete Parameter:

Präanalytik

Getestete Parameter:

Ringversuch für Molekularbiologie, Gruppe 2:

TPMT*2 (TPMT, NM_000367...., TPMT*3B (TPMT, NM_000367..., TPMT*3C (TPMT, NM_000367..., Thiopurine S-methyltrans..., CYP2C8*3 (CYP2C8, NM_000..., CYP2C9*2 (CYP2C9, NM_000..., CYP2C9*3 (CYP2C9, NM_000..., CYP2C9 - 2C9 - Genotypis..., UGT1A1*28 (UGT1A1, NM_00..., DPYD*2A (DPYD, NM_000110..., DPYD*13 (DPYD, NM_000110..., DPYD p.D949V (DPYD, NM_0..., DPYD c.1236G>A (DPYD, NM..., DPD activity score acc. ..., DPD activity score acc. ..., CYP2D6*2-296 (CYP2D6*2, ..., CYP2D6*3 (CYP2D6*3, NM_0..., CYP2D6*4 (CYP2D6*4, NM_0..., CYP2D6*6 (CYP2D6*6, NM_0..., CYP2D6*7 (CYP2D6*7, NM_0..., CYP2D6*8 (CYP2D6*8, NM_0..., CYP2D6*9 (CYP2D6*9, NM_0..., CYP2D6*10 (CYP2D6*10, NM..., CYP2D6*35 (CYP2D6*35, NM..., CYP2D6*41 (CYP2D6*41, NM..., CYP2D6*5 (CYP2D6, Deleti..., CYP2D6*xN (CYP2D6, Dupli..., CYP2C19*2 (CYP2C19, NM_0..., CYP2C19*3 (CYP2C19, NM_0..., CYP2C19*17 (CYP2C19, NM_..., CYP2C19 Genotypisierung HLA B*57:01 (HLA-B, NM_0..., CYP2B6*4 (CYP2B6, NM_000..., CYP2B6*9 (CYP2B6, NM_000..., CYP2B6*6 (NM_000767.5:c...., CYP3A4*22 (CYP3A4, NM_01..., Cyp2D6 Genotyp

Getestete Parameter:

Ringversuch für Molekularbiologie, Gruppe 1:

FV-Leiden (F5, NM_000130..., FII g20210a (F2, NM_0005..., MTHFR C677T (MTHFR, NM_0..., MTHFR A1298C (MTHFR, NM_..., PAI-I 4G5G (SERPINE1, NM..., GPIIIa (ITGB3, NM_000212..., VKORC1 G-1639 (VKORC1, N..., VKORC1 C1173T (VKORC1, N..., FXII c46t (F12, NM_00050..., FV-H1299R (F5, NM_000130..., AAT-PI*S (SERPINA1, NM_0..., AAT-PI*Z (SERPINA1, NM_0..., AAT, Alpha-1-Antitrypsin..., ApoE2 (APOE, NM_000041.4..., ApoE4 (APOE, NM_000041.4..., ApoE, Apolipoprotein E –..., ApoB100 (APOB, NM_000384..., ACE I/D(NM_000789.3:c.23..., HFE H63D (HFE, NM_000410..., HFE S65C (HFE, NM_000410..., HFE C282Y (HFE, NM_00041..., LCT c-13910t (LCT, NM_00..., Faktor VII (R353Q) (F7, ..., AT3 Cambridge Typ I/II (... CYP3A5*3 (CYP3A5, NM_000..